A phase II study for metabolic <it>in vivo </it>response monitoring with sequential <sup>18</sup>FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial

A phase II study for metabolic <it>in vivo </it>response monitoring with sequential <sup>18</sup>FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial

<p>Abstract</p> <p>Background</p> <p>The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolis...

Full description

Bibliographic Details
Main Authors: Berger Anne, von Gall Carl, Abel Ulrich, Delorme Stefan, Kloor Matthias, Ose Jennifer, Weber Tim, Stange Annika, Haag Georg, Haberkorn Uwe, Lordick Florian, Jäger Dirk
Format: Article
Language:English
Published: BMC 2012-03-01
Series:BMC Cancer
Subjects:
Colorectal cancer
Metastases
Cetuximab
Metabolic imaging
<sup>18</sup>F-FDG PET CT
Online Access:http://www.biomedcentral.com/1471-2407/12/108

Internet

http://www.biomedcentral.com/1471-2407/12/108

Similar Items